MRSA detection technology earns first patent

Translational Genomics Research Institute in Phoenix and Northern Arizona University in Flagstaff developed a new technology to detect antibiotic-resistant infections that just received its first patent from Australia.

This "superbug" test can precisely identify multiple types of drug-resistant Staphylococcus bacterial infections in one hour, including Methicillin-resistant Staphylococcus aureus — an antibiotic-resistant form of the Staph bacteria that kills more Americans than HIV every year.

The Staphylococcus Test uses three different proprietary biomarker targets to determine which types of Staph are present and which carry the antibiotic-resistant gene.

The technology, licensed by St. George, Utah-based DxNA, allows for more rapid diagnosis, improved treatment of patients and reduced medical costs.

TGen and NAU expect future patent approvals for the technology from the U.S., Canada, European Union, Japan and Brazil.

More articles on supply chain:

Failed drug study opens door to cheaper drug development: 3 things to know
Some weight loss drugs more effective than others: 6 findings
Novartis clashes with Colombia over high drug costs

 

 

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Content

Featured Webinars

Featured Whitepapers